Clinical Trial Update: An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

An open-label Phase 3 study evaluating different dosing regimens of efgartigimod IV in generalized myasthenia gravis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Generalized Myasthenia Gravis, MG - Myasthenia Gravis | Phase 3 | Status: COMPLETED